Heron Neutron Medical Corp. Files OTC Listing Application, Expected to Begin Trading in Late November

Source: Wealth Magazine Bulletin & OTC Market Announcement

Heron Neutron Medical Corp., a company invested by Hermes-Epitek Corp., submitted application documents on November 1, 2024, and is expected to begin trading on the over-the-counter (OTC) market in late November, in accordance with the timetable announced by the Taipei Exchange and the OTC market.

 

Hermes-Epitek Corp. established Heron in 2017, transferring technology from National Tsing Hua University and the Industrial Technology Research Institute to develop Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) cancer treatment systems. The company currently has a paid-in capital of approximately NT$1.393 billion, with Chin Yung Shu serving as Chairman and Leo Shen as General Manager. 

 

AB-BNCT is a type of targeted radiotherapy that enables non-toxic boron-containing drugs to be selectively absorbed by tumor cells. Under neutron irradiation, boron-10 captures neutrons and produces high linear energy transfer particles that destroy cancer cells while minimizing damage to surrounding healthy tissue. 

 

The AB-BNCT system received medical device approval in August, and the company plans to initiate clinical trials this year in collaboration with leading CDMO drug manufacturers focusing on boron drugs targeting recurrent head and neck cancers. Research will also be conducted on multiple cancer types including meningioma, brain cancer, breast cancer, and lung cancer. Once completed, the technology may be used for emergency medical treatment.